Detalhe da pesquisa
1.
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop).
Eur J Neurol
; 31(6): e16250, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38549186
2.
Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study.
J Neurol Neurosurg Psychiatry
; 94(3): 201-210, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36460438
3.
Disability accrual in primary and secondary progressive multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 94(9): 707-717, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37068931
4.
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
J Neurol Neurosurg Psychiatry
; 94(12): 1004-1011, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414534
5.
Comparative effectiveness in multiple sclerosis: A methodological comparison.
Mult Scler
; 29(3): 326-332, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36800908
6.
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis.
Eur J Neurol
; 30(4): 1014-1024, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36692895
7.
Oligoclonal bands: clinical utility and interpretation cues.
Crit Rev Clin Lab Sci
; 59(6): 391-404, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35277112
8.
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 2022 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36180219
9.
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies.
Mult Scler
; 28(13): 2106-2111, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35735030
10.
Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.
Mult Scler
; 28(11): 1752-1761, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35373638
11.
Serum neurofilament light as biomarker of seizure-related neuronal injury in status epilepticus.
Epilepsia
; 63(1): e23-e29, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34806176
12.
Confirmed disability progression as a marker of permanent disability in multiple sclerosis.
Eur J Neurol
; 29(8): 2321-2334, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35582938
13.
Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score.
Mult Scler
; 27(5): 695-705, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32639855
14.
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.
Mult Scler
; 27(3): 430-438, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33210986
15.
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis.
Mult Scler
; 27(5): 755-766, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32538713
16.
Determinants of therapeutic lag in multiple sclerosis.
Mult Scler
; 27(12): 1838-1851, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33423618
17.
Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy.
Neuroepidemiology
; 55(3): 224-231, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33965951
18.
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study.
Eur J Neurol
; 28(4): 1299-1307, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33305459
19.
Delay from treatment start to full effect of immunotherapies for multiple sclerosis.
Brain
; 143(9): 2742-2756, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32947619
20.
Early clinical markers of aggressive multiple sclerosis.
Brain
; 143(5): 1400-1413, 2020 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32386427